Atlas Trials

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

Clinical trial NCT01416181 · TERMINATED

Trial details

NCT number
NCT01416181
Sponsor
Biogen
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Secondary Progressive Multiple Sclerosis
Start date
2011-09-13
Primary completion
2015-07-28
Enrollment
889

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.